Glenmark Pharmaceuticals Limited — PPTs, 30-01-2026: Investor Presentation

Glenmark Pharma Q3 FY26 consolidated revenue rose 15.1% YoY to ₹3,900.6 Cr. India led with 22.1% growth, North America's core business grew 4.1% (excluding out-licensing income), Europe gained 9.1%, and Emerging Markets 8.4%. EBITDA hit ₹869.7 Cr with a 22.3% margin. PAT was ₹403.2 Cr, including an exceptional item of ₹184.3 Cr.

The company is strategically focused on its innovative portfolio. Recent developments include the launch of NEBZMART® GFB Smartules® for COPD in India and 4 new injectables in North America. The Monroe manufacturing site also received regulatory clearance to restart operations. Globally, RYALTRIS® is scaling up, and WINLEVI® saw strong uptake in the UK, gaining EU approval with a Q1 FY27 launch planned. New oncology assets like QiNHAYO™, Trastuzumab Rezetecan, and Aumolertinib are set to strengthen market presence, with launches anticipated from FY27 onwards. Management aims to build an innovation-led Glenmark for sustainable growth.